Advanced Filters
noise

Common Cold (Pediatric) Clinical Trials

A listing of Common Cold (Pediatric) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 113 clinical trials
S Sanxi Ai

Different Immunosuppressive Treatment in iMN

The primary objective of this study is to compare the 24 month remission of different immunosuppressive therapies in the treatment of idiopathic membranous nephropathy (iMN)

18 - 80 years of age Both Phase 3
S Sanxi Ai

Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN

The primary objective of this study is to determine whether or not cyclosporine (CsA) combined with RTX is more effective than RTX alone in the treatment of idiopathic membranous nephropathy (iMN).

18 - 80 years of age Both Phase 3

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OMS906 in patients with C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)

18 - 99 years of age Both Phase 2

A Study of BION-1301 in Adults With IgA Nephropathy

Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy

18 - 100 years of age Both Phase 3

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

The ASSIST study is a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs. placebo in subjects with IgA nephropathy (IgAN) while on background standard of care therapy and an SGLT2 inhibitor (SGLT2i).

18 - 100 years of age Both Phase 2

Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.

18 - 99 years of age Both Phase 2

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

The primary objective of this study to evaluate the efficacy of ravulizumab compared with placebo to reduce proteinuria and slow the rate of eGFR decline in adult participants with IgAN who are at risk of disease progression.

18 - 100 years of age Both Phase 3
F Francesco P Schena, MD

Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

Idiopathic immunoglobulin A nephropathy (IgAN) is the most common biopsy-proven glomerulonephritis in the world. Approximately 40% of IgAN patients reach end-stage kidney disease (ESKD) 20 years after their kidney biopsy. The high prevalence of ESKD suggests the need to move from a generalized therapy for all patients to personalized therapy. …

18 - 100 years of age Both Phase 4

An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases

The goal of this clinical study is to evaluate multiple dose levels of povetacicept (ALPN-303) in adults with immunoglobulin A (IgA) nephropathy, membranous nephropathy, lupus-related kidney disease (lupus nephritis). or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis to determine if povetacicept is safe and potentially beneficial in treating these diseases. During …

18 - 100 years of age Both Phase 1/2

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis

18 - 70 years of age Both Phase 3

Rewrite in simple language using AI